NEW Exclusive Interview: This miracle pill could make dogs live longer, with Celine Halioua, Founder & CEO of Loyal
@celinehalioua is building the first drug ever FDA-approved for lifespan extension itself ā starting with dogs. We sat down on Onward to talk about why she thinks longevity is the most under-built frontier in medicine and whatās next for
@loyalfordogs.
We cover:
Why the U.S. healthcare system structurally can't build preventative medicine
The "micro single-payer" reason dogs are the perfect first market
"Save the dogs, save the world" ā Loyal's Tesla-style master plan
The September 2019 FDA pathway change that made the entire company possible
Why big dogs die young (growth hormones that never turn off)
Caloric restriction mimetics ā the second drug, for dogs of any size
Why drug development is mostly logistics and economics, not science
Scenario planning the next five years of biotech
Why Loyal is AI-resistant and AI-amplified
Being fired (and rehired) from the longevity fund ā twice
Bottom 10% of her high school class ā Oxford ā dropping out six months from her PhD
Watch the full episode below ā
šššššššššš
(00:00) Celine Halioua, Founder & CEO of Loyal
(01:36) What is Loyal?
(02:29) Why big dogs die younger
(05:47) How the second drug works
(08:22) First longevity drug in history
(09:37) Why longevity drugs never existed
(16:13) The master plan
(18:23) Private vs Public
(20:00) Three steps to market
(25:55) The regulatory loophole
(29:27) Scenario planning
(31:54) AI and drug development
(35:42) Good scenario
(38:03) Bad scenario
(39:35) Unexpected scenario
(44:06) Why Fundrise
(49:27) Founding story